A review of 6 placebo-controlled clinical trials with one,134 full participants concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) were being related to a better common advancement on the Ashworth scale for spasticity in numerous sclerosis people as opposed with placebo, While thi